10-Q: Kenvue Q3 2025: Sales Decline Amid Kimberly-Clark Merger

Kenvue reported a decline in Q3 2025 net sales and operating income, alongside announcing a definitive merger agreement with Kimberly-Clark Corporation.

Summary

• Net sales decreased by 3.5% to $3.764 billion for Q3 2025 and 3.8% to $11.344 billion for the nine months ended September 28, 2025, compared to the prior year periods.
• Organic sales decreased by 4.4% in Q3 2025 and 3.3% for the nine months, driven by volume declines and unfavorable value realization.
• Net income increased by 3.9% to $398 million in Q3 2025, and for the nine months, it increased by 54.7% to $1.140 billion, largely due to the absence of prior-year impairment charges.
• Gross profit margin expanded by 60 basis points to 59.1% in Q3 2025 and 30 basis points to 58.7% for the nine months, benefiting from supply chain optimization.
• Operating income decreased by 3.8% to $629 million in Q3 2025 but increased by 38.4% to $1.879 billion for the nine months, primarily due to the absence of $578 million in impairment charges from the prior year.
• Restructuring expenses increased significantly to $84 million in Q3 2025 (from $31 million) and $204 million for the nine months (from $120 million) as part of the "Our Vue Forward" initiative.
• A definitive merger agreement with Kimberly-Clark Corporation was announced on November 2, 2025, where Kenvue stockholders will receive 0.14625 shares of K-C common stock and $3.50 in cash per Kenvue share.
• The Skin Health and Beauty segment's long-term outlook was reassessed due to slower growth and declining profitability, leading to a quantitative interim impairment assessment of goodwill, though no impairment charge was recorded as fair value exceeded carrying value by approximately 10%.
• Officials in the U.S. federal government alleged a potential association between in utero acetaminophen exposure and neurological conditions, cautioning against Tylenol use by pregnant women, and the FDA initiated a label change process.

Sentiment

Score: 4

Explanation: While net income increased due to the absence of prior-year impairment charges and gross margins improved, the underlying business performance shows declining net sales and organic sales across all segments, indicating underlying challenges. The announced merger with Kimberly-Clark introduces significant integration risks and uncertainties, and new regulatory/litigation risks for key products like Tylenol add to the cautious outlook.

Positives

• Net income increased by 3.9% to $398 million in Q3 2025 and by 54.7% to $1.140 billion for the nine months ended September 28, 2025, largely due to the absence of prior-year impairment charges.
• Gross profit margin expanded by 60 basis points to 59.1% in Q3 2025 and 30 basis points to 58.7% for the nine months, driven by supply chain optimization benefits.
• Selling, general, and administrative expenses decreased by 4.9% in Q3 2025 and 5.2% for the nine months, partly due to reduced Separation-related costs and "Our Vue Forward" savings.
• Net cash flows from operating activities increased by $367 million to $1.343 billion for the nine months ended September 28, 2025.
• The Transition Services Agreement program with J&J was completed in April 2025, finalizing the exit of over 2,300 transition services.
• The "Our Vue Forward" initiative is expected to realize annualized pre-tax gross cost savings of approximately $350 million starting in fiscal year 2026.

Negatives

• Net sales decreased by 3.5% to $3.764 billion in Q3 2025 and 3.8% to $11.344 billion for the nine months ended September 28, 2025.
• Organic sales decreased by 4.4% in Q3 2025 and 3.3% for the nine months, driven by volume declines and unfavorable value realization (price investments).
• Volume-related decreases were attributed to changes in shipment timing in China, trade inventory reductions in the U.S., and lower seasonal incidences for pediatric Pain Care, Allergy Care, and Cough and Cold products.
• Skin Health and Beauty segment adjusted operating income decreased by 28.3% in Q3 2025 and 24.7% for the nine months, impacted by higher brand support expenses, volume declines, input cost inflation, and tariffs.
• Self Care segment adjusted operating income decreased by 6.6% in Q3 2025 and 4.7% for the nine months, due to volume declines, input cost inflation, and tariffs.
• Essential Health segment adjusted operating income decreased by 1.9% for the nine months, impacted by volume declines, currency changes, input cost inflation, and tariffs.
• Restructuring expenses increased by $53 million in Q3 2025 and $84 million for the nine months, driven by higher information technology and project-related costs.
• Currency losses on transactions amounted to $20 million in Q3 2025 and $37 million for the nine months.
• The company estimates incremental gross tariff exposure of approximately $150 million annualized.

Risks

• Ability to expand globally, implement digital strategy, and respond to competitive pressure from private-label brands and generics.
• Challenges from the rapidly changing retail landscape, dependence on key retailers, and the emergence of e-commerce.
• Product reliability, safety, and/or efficacy concerns, potentially leading to investigations, regulatory action, lawsuits, recalls, and reputational damage.
• Potential failure to realize expected benefits from strategic initiatives, restructuring, acquisitions, or divestitures, including the proposed Kimberly-Clark transaction.
• Difficulties in establishing, maintaining, protecting, and enforcing intellectual property rights, and addressing counterfeit products.
• Negative publicity and failed marketing efforts.
• Difficulties and delays in manufacturing and supply chain, leading to business interruptions or product shortages.
• Reliance on third-party relationships, global supply chains, and production/distribution processes.
• Interruptions, breaches, or destruction of information technology or operational technology systems.
• Risks associated with the development, deployment, use, and regulation of artificial intelligence.
• Potential for labor disputes, strikes, work stoppages, and the impact of minimum wage increases.
• Inability to attract and retain talented employees and implement succession plans.
• Impact of climate change, extreme weather, natural disasters, and ESG-related legal/regulatory requirements.
• Insurance being unavailable or insufficient to cover losses.
• Legal proceedings related to talc or talc-containing products sold outside the U.S. and Canada, and the ability of J&J to indemnify for U.S. and Canada Talc-Related Liabilities.
• Impact of legal proceedings and the uncertainty of their outcome, including those related to acetaminophen, Zantac, and benzoyl peroxide.
• Changes to applicable laws, regulations, policies, and related interpretations, including export/import and trade laws (tariffs).
• Changes in tax laws and regulations, increased audit scrutiny, and exposure to additional tax liabilities.
• Impact of inflation and fluctuations in interest rates and currency exchange rates.
• Impact of natural disasters, epidemics, pandemics, and global tensions.
• Impact of impairment of goodwill and other intangible assets, particularly for the Skin Health and Beauty segment, where fair value exceeded carrying value by only approximately 10%.
• Ability to maintain satisfactory credit ratings and access credit markets.
• Ability to achieve expected benefits from the Separation from J&J.
• Restrictions on business, potential tax and indemnification liabilities, and substantial charges related to the Separation.
• Failure of rebranding efforts and continued use of legacy J&J branding.
• Substantial indebtedness and restrictions/covenants in debt agreements.
• Uncertainties related to the proposed Kimberly-Clark transaction, including failure to complete, delays, regulatory approvals, shareholder ownership reduction, potential litigation, integration risks, and increased indebtedness for the combined company.

Future Outlook

Kenvue expects to continue paying quarterly cash dividends. The "Our Vue Forward" initiative is projected to achieve annualized pre-tax gross cost savings of approximately $350 million beginning in fiscal year 2026. The relocation to the new research and development building in Summit, New Jersey, is anticipated to be completed through 2026. The proposed merger with Kimberly-Clark is expected to close in the second half of 2026, contingent upon shareholder and regulatory approvals.

Management Comments

• "Our purpose is to realize the extraordinary power of everyday care."
• "Our global scale and the breadth of our brand portfolio are complemented by our well-developed capabilities and accelerated through our digital strategy, allowing us to dynamically capitalize on and respond to current trends impacting our categories and geographic markets."
• "With a sole focus on consumer health, our marketing organization operates efficiently by leveraging our precision marketing, e-commerce, and broader digital capabilities to develop unique consumer insights and further enhance the relevance of our brands."
• "Our research and development organization combines these consumer insights with deep, multi-disciplinary scientific expertise, and engagement with healthcare professionals, to drive innovative new products, solutions, and experiences centered around consumer health."
• "We will continue to monitor the performance of the Skin Health and Beauty business; however, further deterioration of market conditions or an inability of the Company to execute on its strategies could lead to an impairment charge of the goodwill associated with the Skin Health and Beauty reporting unit in the future."
• "We expect to continue to pay cash dividends on a quarterly basis."

Industry Context

The consumer health industry is experiencing shifts in consumer sentiment, changing shopping patterns, and competitive pressures from private-label and generic brands. Regulatory scrutiny on product ingredients (e.g., acetaminophen, BPO) is increasing. Macroeconomic factors like tariffs, inflation, and interest rate fluctuations continue to impact supply chain costs and consumer spending. The proposed merger with Kimberly-Clark indicates a trend towards consolidation in the consumer goods sector to achieve scale and synergies.

Comparison to Industry Standards

• The company's gross profit margin expansion (60 bps in Q3 2025, 30 bps in 9M 2025) suggests effective cost management or pricing power, which could be compared to peers like Procter & Gamble (P&G) or Unilever, though specific benchmarks are not provided in the filing.
• The decline in organic sales across all segments (Self Care -5.3%, Skin Health and Beauty -3.5%, Essential Health -4.2% in Q3 2025) indicates underperformance relative to a growing consumer health market or specific category growth rates seen in competitors. Many consumer staples companies have reported modest organic growth in the low single digits.
• The significant increase in restructuring expenses ($84 million in Q3 2025) suggests a substantial internal transformation effort, which is common in large companies seeking efficiency, but the effectiveness will be measured against the projected $350 million in annual savings by fiscal year 2026.
• The proposed merger with Kimberly-Clark, a major player in personal care and tissue products, would create a combined entity with significant market share, potentially rivaling the scale of consumer health divisions of larger conglomerates or specialized consumer health companies.

Management Changes

Corporate Governance

Legal Proceedings

• Numerous product liability claims and lawsuits involving multiple products, seeking substantial compensatory and punitive damages.
• Lawsuits alleging in utero exposure to acetaminophen (Tylenol) is associated with autism spectrum disorder and/or attention-deficit/hyperactivity disorder in children, with cases in federal multi-district litigation dismissed in favor of JJCI but currently on appeal.
• State of Texas filed a petition in October 2025 against Kenvue, Kenvue Brands LLC, and J&J alleging violations of consumer protection and fraudulent transfer acts related to acetaminophen claims.
• Claims for personal injury and death brought in the UK in October 2025 against Kenvue UK Limited, J&J, and J&J Management Limited regarding Johnson's Baby Powder, alleging mesothelioma, ovarian cancer, lung granulomata, lung fibrosis, and/or uterine fibroids.
• Indemnification demands from Pfizer, Boehringer Ingelheim, and GlaxoSmithKline LLC to J&J related to Zantac sales by Pfizer, which J&J has rejected.
• Canadian class actions and personal injury actions against JJI and J&J related to Zantac products, with one class action stayed and another discontinued. JJI has provided Sanofi notice reserving rights to claim indemnification.
• Putative class actions filed against Kenvue and others following the FDA's proposed order to remove orally administered phenylephrine (PE) from the OTC monograph, alleging consumer protection violations, negligence, and unjust enrichment. These cases are consolidated in federal multi-district litigation, with a streamlined complaint dismissed and on appeal.
• Putative Canadian class actions and representative actions in Australia and New Zealand filed against Kenvue affiliates regarding PE-containing products.
• Two putative securities class actions consolidated as "In re Kenvue Inc. Securities Litigation" and shareholder derivative complaints consolidated as "In re Kenvue, Inc. Derivative Litigation" filed in U.S. District Court for the District of New Jersey, alleging misleading statements and omissions about PE in SEC filings.
• Putative class actions filed against Kenvue and others regarding benzoyl peroxide (BPO) OTC acne products degrading into benzene, alleging consumer protection violations, negligence, and breach of warranties.
• JJCI is a defendant in a cost recovery action by Occidental Chemical Corporation related to the clean-up of the Lower Passaic River in New Jersey.
• Various proceedings under Superfund and comparable laws for environmental investigation and remediation activities.

Related Party Transactions

• Kenvue continues to have material agreements with J&J following the Separation, including the Separation Agreement, Tax Matters Agreement, Transition Services Agreement, and Transition Manufacturing Agreement.
• In April 2025, Kenvue completed its Transition Services Agreement program with J&J, finalizing the exit of over 2,300 transition services.
• Kenvue had a net liability to J&J of $25 million as of September 28, 2025, related to net economic benefit arrangements for Deferred Local Businesses.
• Kenvue had a net liability to J&J totaling approximately $80 million as of September 28, 2025, for income and non-income indemnification tax payables and refunds.
• J&J has retained all Talc-Related Liabilities in the United States and Canada and agreed to indemnify Kenvue for them, while Kenvue remains responsible for talc liabilities outside these regions.

Stakeholder Impact

• Shareholders: Will experience a reduction in direct ownership and voting influence in the combined Kimberly-Clark entity (expected to own ~46%). The value of their consideration is subject to K-C stock price fluctuations. Potential for litigation related to the merger.
• Employees: Subject to global workforce reductions and changes in management structure as part of the "Our Vue Forward" initiative. Uncertainty regarding roles within the combined company post-merger could lead to loss of key employees.
• Customers: May be impacted by strategic price investments, trade inventory reductions, and competitive pressures. Product reliability and safety concerns (acetaminophen, BPO) could affect trust and purchasing decisions.
• Suppliers: Supply chain optimization initiatives and reliance on third-party relationships could impact supplier relationships and terms.
• Creditors: Kimberly-Clark is expected to incur significant additional indebtedness to finance the cash consideration for the merger, which could affect the combined company's credit profile and liquidity.
• Regulatory Bodies: Increased scrutiny and potential regulatory actions related to product safety (acetaminophen, PE, BPO) and environmental matters.

Next Steps

• Complete the relocation to the new research and development building in Summit, New Jersey, through 2026.
• Continue to monitor the performance of the Skin Health and Beauty business to assess potential future goodwill impairment.
• Monitor any changes to the OECD Pillar Two framework and enacted Pillar Two legislation.
• Continue to assess the impact of the OBBBA on financial statements.
• Seek shareholder approval for the merger agreement and K-C stockholder approval for K-C common stock issuance.
• Obtain antitrust clearance in the United States and other foreign regulatory approvals for the Kimberly-Clark merger.
• Complete the proposed merger with Kimberly-Clark in the second half of 2026.
• Kenvue Brands LLC will continue to respond to citizen petitions and litigation regarding acetaminophen.
• The company expects to continue paying quarterly cash dividends.

Key Dates

Recommendation

While Kenvue shows some operational improvements like gross margin expansion and cost savings from restructuring, the core business is experiencing declining net and organic sales across all segments, indicating underlying challenges. The proposed merger with Kimberly-Clark introduces significant strategic changes and integration risks, and the terms of the deal mean Kenvue shareholders will have a reduced stake in a larger, more diversified entity. New regulatory and litigation risks surrounding key products like Tylenol add further uncertainty. Given the mixed operational performance and the pending, complex merger, a "Hold" recommendation is appropriate. Investors should await further clarity on the merger's progression, integration plans, and the combined entity's future performance before making significant investment decisions.

Keywords

Consumer health, Kenvue, Kimberly-Clark, merger, acquisition, SEC filing, 10-Q, financial results, net sales, operating income, organic sales, restructuring, supply chain, Tylenol, acetaminophen, Dr.Ci:Labo, Skin Health and Beauty, Self Care, Essential Health, goodwill, impairment, tariffs, legal proceedings, product liability, corporate governance, stock options, RSUs